Last reviewed · How we verify
NCT03274752: CARE-AMI
Paroxetine-mediated GRK2 Inhibition to Reduce Cardiac Remodeling After Acute Myocardial Infarction
Phase 2 trial testing Paroxetine in Cardiac Remodeling in 50 participants. Completed in 1 March 2022.
1 January 2021
Quick facts
| Lead sponsor | Insel Gruppe AG, University Hospital Bern |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 50 |
| Start date | 26 October 2017 |
| Primary completion | 1 January 2021 |
| Estimated completion | 1 March 2022 |
| Sites | 1 location across Switzerland |
Drugs / interventions tested
- Paroxetine — full drug profile →
- Placebo oral capsule
Conditions studied
- Cardiac Remodeling — all drugs for Cardiac Remodeling →
- Myocardial Infarction — all drugs for Myocardial Infarction →
Sponsor
Insel Gruppe AG, University Hospital Bern
Who can join
18 and older, any sex, with Cardiac Remodeling or Myocardial Infarction. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study evaluates the off-target effect of paroxetine to reverse cardiac remodeling and improve left ventricular ejection fraction in patients after acute myocardial infarction. Half of the participants will receive paroxetine, while the other half will receive placebo treatment.
Publications & conference data
6 peer-reviewed publications reference this trial (live from Europe PMC):
-
Post-myocardial infarction fibrosis: Pathophysiology, examination, and intervention.
Yin X, Yin X, Pan X, Zhang J, et al · · 2023 · cited 50× · PMID 37056987 · DOI 10.3389/fphar.2023.1070973 -
Effect of Paroxetine-Mediated G-Protein Receptor Kinase 2 Inhibition vs Placebo in Patients With Anterior Myocardial Infarction: A Randomized Clinical Trial.
Pilgrim T, Vollenbroich R, Deckarm S, Gräni C, et al · · 2021 · cited 16× · PMID 34259826 · DOI 10.1001/jamacardio.2021.2247 -
Antidepressant treatment in patients following acute coronary syndromes: a systematic review and Bayesian meta-analysis.
Sweda R, Siontis GCM, Nikolakopoulou A, Windecker S, et al · · 2020 · cited 15× · PMID 32935927 · DOI 10.1002/ehf2.12861 -
Diagnostic performance of cardiac magnetic resonance segmental myocardial strain for detecting microvascular obstruction and late gadolinium enhancement in patients presenting after a ST-elevation myocardial infarction.
Gräni C, Stark AW, Fischer K, Fürholz M, et al · · 2022 · cited 14× · PMID 35911559 · DOI 10.3389/fcvm.2022.909204 -
Regulation of β-Adrenergic Receptors in the Heart: A Review on Emerging Therapeutic Strategies for Heart Failure.
Parichatikanond W, Duangrat R, Kurose H, Mangmool S. · · 2024 · cited 13× · PMID 39451192 · DOI 10.3390/cells13201674 -
Paroxetine-Mediated G-Protein Receptor Kinase 2 Inhibition in Patients With Acute Anterior Myocardial Infarction: Final 1-Year Outcomes of the Randomized CARE-AMI Trial.
Pilgrim T, Bernhard B, Fürholz M, Vollenbroich R, et al · · 2022 · cited 5× · PMID 36000427 · DOI 10.1161/jaha.122.026362
Verify or expand the search:
- PubMed search for NCT03274752
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Paroxetine
Trials testing the same drug.
- NCT06763484 — Paroxetine Versus Placebo for Vasomotor Symptom Management in Surgical Menopause · Phase 2 · completed
- NCT06232109 — Drug-Drug Interaction of ASN51 With Fluvoxamine, Itraconazole and Paroxetine in Healthy Subjects · Phase 1 · completed
- NCT06231745 — Paroxetine Safety and Efficacy in Rheumatoid Arthritis · Phase 3 · recruiting
- NCT06049797 — A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats · active not recruiting
- NCT06065735 — Concentration-QT Study of Paroxetine in Healthy Adults · Phase 1 · completed
Other recruiting trials for Cardiac Remodeling
Currently open trials in the same condition.
- NCT06901609 — Effect of Genetic Polymorphism on the Clinical Outcome to SGLT2 Inhibitors in Heart Failure Patients · active not recruiting
Other Insel Gruppe AG, University Hospital Bern trials
Trials by the same sponsor.
- NCT06546384 — GLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease · NA · not yet recruiting
- NCT07524049 — Giving Children a Voice in Paediatric Anaesthesia · not yet recruiting
- NCT07415668 — Motor Eloquent Navigated Transcranial Magnetic Stimulation for Radiosurgery Planning · NA · not yet recruiting
- NCT07478536 — Stockholm3 Test Validation in Men on Active Surveillance in Switzerland (CHAS3 Trial) · not yet recruiting
- NCT07201506 — Real-Time Intracardiac Echocardiography for Ventricular Arrhythmia Ablation · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03274752 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Insel Gruppe AG, University Hospital Bern
- Last refreshed: 1 June 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03274752.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing